# Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma

> **NCT05609695** · — · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 100 (estimated)

## Conditions studied

- Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma

## Interventions

- **DRUG:** Immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT05609695
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05609695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05609695, "Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05609695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*